Scholl Hendrik Peter, the Chief Medical Officer of Belite Bio, Inc., has reported the sale of 2,000 American depositary shares. This transaction is part of a pre-established trading plan and was filed with the SEC on November 16, 2026. The sales occurred on November 12, 2026, and are significant as they reflect the ongoing stock transactions by key executives in the company.

Belite Bio, Inc. is a company focused on pharmaceutical preparations, specifically within the life sciences sector. The company is incorporated in the United States and trades under the symbol BLTE. Recent filings indicate that Scholl Hendrik Peter has been actively managing his stock holdings, as evidenced by multiple transactions reported in the past months.

According to the filing, Scholl sold 500 shares at prices ranging from $162.0394 to $170.4094 per share. Following these transactions, he retains ownership of 12,500 shares. The sales were conducted under a Rule 10b5-1 trading plan, which allows executives to schedule sales of their stock in advance to avoid any potential allegations of insider trading.

This update may influence investor sentiment as it highlights the trading activities of a key executive within Belite Bio. The pharmaceutical preparations industry often scrutinizes such transactions, as they can signal confidence or concerns about the company's future performance. The structured nature of the trading plan suggests a strategic approach to managing stock sales.

The filing does not specify what actions may follow this transaction. However, the continued activity in Scholl's stock holdings indicates a proactive management of his investment in Belite Bio.